Introduction
Methods
Data source
Participant selection
Predictors of 30-day mortality in SAE patients
Statistical analysis
Results
Baseline characteristic
Variables | Survival (n = 5762) | Death (n = 1232) | P Value |
---|---|---|---|
Demographics | |||
Age (y), median [Q1, Q3] | 70.00 (58.00,81.00) | 77.00 (66.00,85.25) | < 0.001 |
Male, n (%) | 3181 (55.21) | 659 (53.49) | 0.286 |
Race, n (%) | 0.001 | ||
Black | 490 (8.50) | 93 (7.55) | |
White | 4000 (69.42) | 824 (66.88) | |
Hispanic | 174 (3.02) | 31 (2.52) | |
Asian | 193 (3.35) | 31 (2.52) | |
Others | 905 (15.71) | 253 (20.54) | |
Coexisting disorders, n (%) | |||
Myocardial infarction | 1006 (17.46) | 265 (21.51) | 0.001 |
Congestive heart failure | 1977 (34.31) | 540 (43.83) | < 0.001 |
Peripheral vascular disease | 696 (12.08) | 174 (14.12) | 0.054 |
Cerebrovascular disease | 259 (4.49) | 51 (4.14) | 0.636 |
Dementia | 300 (5.21) | 81 (6.57) | 0.064 |
Chronic pulmonary disease | 1728 (29.99) | 421 (34.17) | 0.004 |
Rheumatic disease | 234 (4.06) | 79 (6.41) | < 0.001 |
Peptic ulcer disease | 229 (3.97) | 64 (5.19) | 0.063 |
Mild liver disease | 709 (12.30) | 242 (19.64) | < 0.001 |
Diabetes without complication | 1308 (22.70) | 255 (20.70) | 0.135 |
Diabetes with complication | 507 (8.80) | 105 (8.52) | 0.798 |
Paraplegia | 124 (2.15) | 17 (1.38) | 0.101 |
Renal disease | 1349 (23.41) | 387 (31.41) | < 0.001 |
Malignant cancer | 839 (14.56) | 342 (27.76) | < 0.001 |
Severe liver disease | 225 (3.90) | 93 (7.55) | < 0.001 |
Metastatic solid tumor | 343 (5.95) | 205 (16.64) | < 0.001 |
AIDS | 41 (0.71) | 10 (0.81) | 0.849 |
CCI, median [Q1, Q3] | 6.00 (4.00,8.00) | 7.00 (6.00,9.00) | < 0.001 |
Vital signs (1st 24 h) | |||
Temperature (°C), median [Q1, Q3] | 36.90 (36.60,37.30) | 36.70 (36.40,37.10) | < 0.001 |
MAP (mmHg), median [Q1, Q3] | 75.00 (70.00,82.00) | 73.00 (68.00,80.00) | < 0.001 |
Heart rate (min), median [Q1, Q3] | 88.00 (77.00,100.00) | 91.00 (80.00,104.00) | < 0.001 |
Respiratory rate (min), median [Q1, Q3] | 20.00 (17.00,23.00) | 22.00 (19.00,25.00) | < 0.001 |
Laboratory findings (1st 24 h) | |||
RBC (× 109/L), median [Q1, Q3] | 3.41 (3.02,3.92) | 3.28 (2.88,3.80) | < 0.001 |
WBC (× 109/L), median [Q1, Q3] | 11.80 (8.60,16.03) | 12.62 (8.77,17.50) | 0.002 |
MCH (pg), median [Q1, Q3] | 30.20 (28.73,31.50) | 30.12 (28.70,31.63) | 0.925 |
MCHC (%), median [Q1, Q3] | 33.00 (31.85,34.00) | 32.40 (31.30,33.50) | < 0.001 |
MCV (fL), median [Q1, Q3] | 91.00 (87.00,95.00) | 92.75 (88.00,97.33) | < 0.001 |
PLT (× 109/L), median [Q1, Q3] | 197.00 (139.00,268.50) | 189.33 (116.71,272.75) | 0.001 |
RDW (%), median [Q1, Q3] | 14.77 (13.73,16.27) | 16.00 (14.58,18.00) | < 0.001 |
HCT (%), median [Q1, Q3] | 31.30 (27.78,35.70) | 30.38 (26.80,35.07) | < 0.001 |
APTT (s), median [Q1, Q3] | 31.90 (27.80,39.80) | 35.70 (29.30,49.50) | < 0.001 |
PT (s), median [Q1, Q3] | 14.27 (12.85,16.50) | 15.70 (13.40,20.00) | < 0.001 |
INR, median [Q1, Q3] | 1.30 (1.15,1.50) | 1.40 (1.20,1.85) | < 0.001 |
pH, median [Q1, Q3] | 7.37 (7.32,7.42) | 7.36 (7.31,7.42) | < 0.001 |
Bicarbonate (mmol/L), median [Q1, Q3] | 23.00 (20.50,26.00) | 21.90 (19.00,25.50) | < 0.001 |
Lactate (mmol/L), median [Q1, Q3] | 1.65 (1.20,2.28) | 1.95 (1.40,2.89) | < 0.001 |
BE (mEq/L), median [Q1, Q3] | -0.50 (-3.50,1.43) | -1.33 (-5.00,1.00) | < 0.001 |
Aniongap (mmol/L), median [Q1, Q3] | 14.00 (12.00,16.50) | 15.50 (13.00,18.21) | < 0.001 |
PaO2 (mmHg), median [Q1, Q3] | 112.00 (76.00,173.00) | 92.00 (68.00,131.00) | < 0.001 |
PaCO2 (mmHg), median [Q1, Q3] | 41.00 (37.00,47.00) | 41.00 (35.00,48.00) | 0.014 |
Chloride (mmol/L), median [Q1, Q3] | 104.50 (100.50,108.20) | 103.00 (98.75,107.50) | < 0.001 |
Calcium (mmol/L), median [Q1, Q3] | 8.20 (7.73,8.63) | 8.10 (7.63,8.65) | 0.097 |
Sodium (mmol/L), median [Q1, Q3] | 138.60 (136.00,141.00) | 138.00 (134.82,141.43) | 0.001 |
Potassium (mmol/L), median [Q1, Q3] | 4.15 (3.83,4.55) | 4.28 (3.88,4.78) | < 0.001 |
Glucose (mmol/L), median [Q1, Q3] | 128.50 (108.33,156.24) | 131.00 (107.00,163.54) | 0.130 |
CRE (mg/dL), median [Q1, Q3] | 1.05 (0.75,1.68) | 1.35 (0.85,2.30) | < 0.001 |
BUN (mg/dL), median [Q1, Q3] | 22.29 (15.00,37.67) | 32.58 (20.67,52.35) | < 0.001 |
Therapy (1st 24 h), n (%) | |||
Vasopressor | 1799 (31.22) | 538 (43.67) | < 0.001 |
Scoring system | |||
GCS | 13.00 (9.00,14.00) | 8.00 (3.00,12.00) | < 0.001 |
SOFA | 6.00 (4.00,9.00) | 9.00 (6.00,12.00) | < 0.001 |
APSIII | 55.00 (41.00,72.00) | 80.50 (63.00,102.00) | < 0.001 |
SIRS | 3.00 (2.00,3.00) | 3.00 (2.75,4.00) | < 0.001 |
Variable importance
Comparisons among different ML models
Model | Accuracy | Sensitivity | Specificity | PPV | NPV | AUC | Operating threshold | 95% CI |
---|---|---|---|---|---|---|---|---|
NNET | 0.840 | 0.802 | 0.733 | 0.391 | 0.946 | 0.833 | 0.164 | (0.816, 0.849) |
NB | 0.833 | 0.767 | 0.800 | 0.450 | 0.941 | 0.816 | 0.058 | (0.799, 0.833) |
LR | 0.843 | 0.808 | 0.731 | 0.391 | 0.947 | 0.833 | 0.162 | (0.816, 0.848) |
GBM | 0.844 | 0.805 | 0.699 | 0.360 | 0.944 | 0.824 | 0.141 | (0.807, 0.840) |
Ada | 0.846 | 0.786 | 0.737 | 0.390 | 0.942 | 0.834 | 0.148 | (0.817, 0.849) |
RF | 0.840 | 0.856 | 0.642 | 0.338 | 0.954 | 0.825 | 0.150 | (0.808, 0.841) |
BT | 0.836 | 0.715 | 0.745 | 0.375 | 0.925 | 0.804 | 0.240 | (0.786, 0.820) |
XGB | 0.844 | 0.808 | 0.712 | 0.374 | 0.945 | 0.830 | 0.157 | (0.814, 0.846) |
CatBoost | 0.842 | 0.789 | 0.741 | 0.394 | 0.943 | 0.830 | 0.165 | (0.813, 0.846) |